Are there any differences in the regulations of personalized medicine among the USA, EU and Japan?

por Shimazawa, Rumiko, Ikeda, Masayuki
Publicado 2013

Approval status and evidence for WHO essential medicines for children in the United States, United Kingdom, and Japan: a cross-sectional study

por Shimazawa, Rumiko, Ikeda, Masayuki
Publicado 2017

Challenges to hemoglobin A1c as a therapeutic target for type 2 diabetes mellitus

por Ikeda, Masayuki, Shimazawa, Rumiko
Publicado 2019

Imbalance in glycemic control between the treatment and placebo groups in cardiovascular outcome trials in type 2 diabetes

por Shimazawa, Rumiko, Ikeda, Masayuki
Publicado 2019

Potential adverse events in Japanese women who received tozinameran (BNT162b2, Pfizer-BioNTech)

por Shimazawa, Rumiko, Ikeda, Masayuki
Publicado 2021

Natural language processing‐based assessment of consistency in summaries of product characteristics of generic antimicrobials

por Shimazawa, Rumiko, Kano, Yoshinobu, Ikeda, Masayuki
Publicado 2018

Guidance for peptide vaccines for the treatment of cancer

por Yamaguchi, Yoshiyuki, Yamaue, Hiroki, Okusaka, Takuji, Okuno, Kiyotaka, Suzuki, Hiroyuki, Fujioka, Tomoaki, Otsu, Atsushi, Ohashi, Yasuo, Shimazawa, Rumiko, Nishio, Kazuto, Furuse, Junji, Minami, Hironobu, Tsunoda, Takuya, Hayashi, Yuzo, Nakamura, Yusuke
Publicado 2014